Teva Pharmaceuticals launches Brinzolamide ophthalmic suspension in the US market.
Economic Times
On 9 March 2021, Indoco Remedies announced the launch of an ophthalmic suspension by Teva Pharmaceuticals. This suspension is used for the treatment of elevated intraocular pressure in patients with ocular hypertension. It is also used to treat open–angle glaucoma in the United States. 1
This product is called Brinzolamide ophthalmic suspension ( 1 percent ). It is the generic version of Azopt ophthalmic suspension. Brinzolamide ophthalmic suspension is developed and manufactured by the Indoco Remedies- Goa facility for Teva pharma.
This ophthalmic suspension works by reducing the amount of fluid in the eye. Brinzolamide ophthalmic suspension 1 percent is the first – to – market a generic version of Azopt in the United States. Indoco Remedies is excited about this and hopes to secure approvals from the US regulator for other complex generic products in the future.
Indoco is headquartered in Mumbai, India, and employs over 5.500 employees. It has around nine manufacturing facilities, and its presence covers over 55 countries.
Read about:
Ocular Drug Delivery Systems: Introduction
Ophthalmic treatments for eye diseases rely mostly on eye drop medication administered to the patients in an outpatient setting. Eye drop administration appears to be easy. However, patients with compromised eyesight may face difficulties. Additionally, drug action duration is shorter, requiring frequent administration (one to eight times a day). This results in the patients’ non-compliance, and they often miss out on the regimen.
Acetazolamide- Ophthalmic preparation for Glaucoma: Acetazolamide causes inhibition of carbonic anhydrase in the CNS, decreasing carbon dioxide tension in the pulmonary alveoli, thus increasing arterial oxygen tension. Acetazolamide thus reduces intra-ocular pressure. It is also used as part of the pre-operative treatment of acute angle-closure glaucoma
Betaxolol is used for Glaucoma: It is a selective blocker of catecholamine stimulation of beta(1)-adrenergic receptors in the heart and vascular smooth muscle.